What is it about?
In Kyrgyzstan, the BPaL regimen was introduced to tackle drug-resistant TB. From 2021–2022, 50 patients achieved an 84% success rate. Despite linezolid-related side effects, proper management ensured safety. Lessons guide nationwide rollout and global TB strategies.
Featured Image
Photo by Ksenia on Unsplash
Why is it important?
The introduction of the BPaL regimen in Kyrgyzstan is vital because it addresses the pressing challenge of drug-resistant tuberculosis (DR-TB), which poses a significant public health threat. Traditional treatments are lengthy, toxic, and often ineffective for fluoroquinolone-resistant TB cases. The BPaL regimen offers a shorter, more effective alternative, improving patient outcomes and quality of life. By documenting the experiences and lessons learned from operational research, Kyrgyzstan contributes valuable insights to global efforts, supporting other high-burden countries in implementing innovative DR-TB solutions. This initiative also strengthens the global response to achieving WHO’s "End TB" strategy goals.
Perspectives
The introduction of the BPaL regimen in Kyrgyzstan offers significant public health and global implications. By providing a shorter, more effective treatment for fluoroquinolone-resistant TB, it improves patient outcomes, reduces transmission, and sets a model for other high-burden countries. This experience highlights the importance of operational research, ensuring effective patient monitoring, adverse event management, and psychological support to maximize treatment success. Kyrgyzstan’s lessons contribute to global TB strategies, fostering collaboration and guiding the implementation of innovative regimens like BPaLM, ultimately advancing efforts to achieve WHO’s "End TB" goals.
Dr. Bakyt Bolotbekovich Myrzaliev
KNCV Tuberculosefonds
Read the Original
This page is a summary of: Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, August 2024, Elsevier,
DOI: 10.1016/j.jctube.2024.100472.
You can read the full text:
Contributors
The following have contributed to this page
